Repeated citalopram treatment but not stress exposure attenuates hypothalamic-pituitary-adrenocortical axis response to acute citalopram injection

Life Sciences

Volumn 72, Issue 12, 2003, Pages 1353-1365

  Moncek, Fedor ^a   Duncko, Roman ^a   Jezova, Daniela ^a  

^a INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

Citalopram; CRH gene expression; HPA axis; Serotonin reuptake; Stress

Indexed keywords

CITALOPRAM; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; MESSENGER RNA; NEUROPEPTIDE; PROOPIOMELANOCORTIN; SEROTONIN;

ADENOHYPOPHYSIS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; IMMOBILIZATION STRESS; MALE; MEASUREMENT; NEUROTRANSMISSION; NONHUMAN; RAT; SEROTONINERGIC SYSTEM; STRESS; WEIGHT GAIN;

ADRENAL CORTEX; ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; GENE EXPRESSION; HYPOTHALAMUS; MALE; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PITUITARY GLAND; PITUITARY GLAND, ANTERIOR; PRO-OPIOMELANOCORTIN; RATS; RATS, WISTAR; RESTRAINT, PHYSICAL; RNA, MESSENGER; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; STRESS; WEIGHT GAIN;

ANIMALIA;

EID: 0037422966     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)02409-8     Document Type: Article

References (54)

1. Abd Elaziz M.A., Al-Dhawailie A.A., Tekle A. The effect of stress on the pharmacokinetics and pharmacodynamics of glibenclamide in diabetic rats. European Journal of Drug Metabolism and Pharmacokinetics. 23(3):1998;371-376.
2. Appelbaum B.D., Holtzman S.G. Stress-induced changes in the analgesic and thermic effects of morphine administered centrally. Brain Research. 358(1-2):1985;303-308.
3. Calogero A.E., Bagdy G., Szemeredi K., Tartaglia M.E., Gold P.W., Chrousos G.P. Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. Endocrinology. 126(4):1990;1888-1894.
4. Dekeyne A., Denorme B., Monneyron S., Millan M.J. Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors. Neuropharmacology. 39(6):2000;1114-1117.
5. Duncan G.E., Knapp D.J., Carson S.W., Breese G.R. Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone. Journal of Pharmacology and Experimental Therapeutics. 285(2):1998;579-587.
6. Dunn A.J., File S.E. Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Hormones and Behaviour. 21(2):1987;193-202.
7. Fernandez F., Coomans V., Mormede P., Chaouloff F. Effects of corticosterone ingestion on hippocampal [(3)H]serotonin reuptake in inbred rat strains. Endocrine Regulations. 35(3):2001;119-126.
8. File S.E., Zangrossi H. Jr., Andrews N. Novel environment and cat odor change GABA and 5-HT release and uptake in the rat. Pharmacology Biochemistry Behavior. 45(4):1993;931-934.
9. Gobbi M., Crespi D., Foddi M.C., Fracasso C., Mancini L., Parotti L., Mennini T. Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats. Naunyn Schmiedeberg's Archives of Pharmacology. 356(1):1997;22-28.
10. Harvey B.H., Bouwer C.D. Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clinical Neuropharmacology. 23(2):2000;90-97.
11. Hashimoto S., Inoue T., Koyama T. Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Psychopharmacology (Berlin). 123(2):1996;182-186.
12. Hidalgo R.B., Davidson J.R. Selective serotonin reuptake inhibitors in post-traumatic stress disorder. Journal of Psychopharmacology. 14(1):2000;70-76.
13. Holsboer F., Lauer C.J., Schreiber W., Krieg J.C. Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology. 62(4):1995;340-347.
14. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocrine Reviews. 17(2):1996;187-205.
15. Hyttel J., Overo K.F., Arnt J. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology (Berlin). 83:1984;20-27.
16. Jensen J.B., Jessop D.S., Harbuz M.S., Mork A., Sanchez C., Mikkelsen J.D. Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. Journal of Neuroendocrinology. 11(6):1999;465-471.
17. Jensen J.B., Mork A., Mikkelsen J.D. Chronic Antidepressant Treatments Decrease Pro-Opiomelanocortin mRNA Expression in the Pituitary Gland: Effects of Acute Stress and 5-HT1A Receptor Activation. Journal of Neuroendocrinology. 13(10):2001;887-893.
18. Jezova D., Jurcovicova J., Vigas M., Labrie F. Possible mechanisms involved in naloxone-, morphine- and stress-induced ACTH release in rats. Usdin E., Kvetnansky R., Axelrod J. Stress: The Role of Catecholamines and Other Neurotransmitters. 1984;263-273 Gordon and Breach Science Publishers, New York.
19. Jezova D., Kvetnansky R., Kovacs K., Oprsalova Z., Vigas M., Makara G.B. Insuline-induced hypoglycemia activates the release of adrenocorticotropin predominantly via central and propranolol insensitive mechanisms. Endocrinology. 120(1):1987;409-415.
20. Jezova D., Guillaume V., Jurankova E., Carayon P., Oliver C. Studies of the physiological role of ANF in ACTH regulation. Endocrine Regulations. 28(4):1994;163-169.
21. Jezova D., Skultetyova I. Neuroendocrine response in stress - a specific activation by individual stressors. Archives of Physiology and Biochemistry. 105:1997;233-237.
22. Jezova D., Ochedalski T., Glickman M., Kiss A., Aguilera G. Central corticotropin-releasing hormone receptors modulate hypothalamic-pituitary-adrenocortical and sympathoadrenal activity during stress. Neuroscience. 94(3):1999;797-802.
23. Kageyama K., Tozawa F., Horiba N., Watanobe H., Suda T. Serotonin stimulates corticotropin-releasing factor gene expression in the hypothalamic paraventricular nucleus of conscious rats. Neuroscience Letters. 243(1-3):1998;17-20.
24. Kapitany T., Schindl M., Schindler S.D., Hesselmann B., Fureder T., Barnas C., Sieghart W., Kasper S. The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Research. 88(2):1999;75-88.
25. Koob G.F., Thatcher-Britton K. Stimulant and anxiogenic effects of corticotropin releasing factor. Progress in Clinical Biology Research. 192:1985;499-506.
26. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with folin phenol reagent. Journal of Biological Chemistry. 193:1951;256-272.
27. Martin C., Duclos M., Mormede P., Manier G., Chaouloff F. Hippocampal and striatal [(3)H]5-HT reuptake under acute stressors in two rat strains differing for their emotivity. Neuroscience Letters. 288:2000;246-248.
28. Matto V., Harro J., Allikmets L. The effects of cholecystokinin A and B receptor antagonists, devazepide and L 365260, on citalopram-induced decrease of exploratory behaviour in rat. Journal of Physiology and Pharmacology. 47(4):1996;661-669.
29. Mennini T., Taddei C., Codegoni A., Gobbi M., Garattini S. Acute noise stress reduces [3H]5-hydroxytryptamine uptake in rat brain synaptosomes: protective effects of buspirone and tianeptine. European Journal of Pharmacology. 241(2-3):1993;255-260.
30. Moncek F., Kvetnansky R., Jezova D. Differential responses to stress stimuli of Lewis and Fischer rats at the pituitary and adrenocortical level. Endocrine Regulations. 35(1):2001;35-41.
31. Muscat R., Papp M., Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology (Berlin). 109(4):1992;433-438.
32. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. Journal of Pharmacology Experimental Therapeutics. 283(3):1997;1305-1322.
33. Pacak K., Palkovits M. Stressor specificity of central neuroendocrine responses: implications for stress-related disorders. Endocrine Reviews. 22(4):2001;502-548.
34. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biological Psychiatry. 49(5):2001;391-404.
35. Piazza P.V., Le Moal M. The role of stress in drug self-administration. Trends in Pharmacological Sciences. 19(2):1998;67-74.
36. Pineyro G., Blier P., Dennis T., de Montigny C. Desensitization of the neuronal 5-HT carrier following its long-term blockade. Journal of Neuroscience. 14(5 Pt 2):1994;3036-3047.
37. Pollier F., Sarre S., Aguerre S., Ebinger G., Mormede P., Michotte Y., Chaouloff F. Serotonin reuptake inhibition by citalopram in rat strains differing for their emotionality. Neuropsychopharmacology. 22(1):2000;64-76.
38. Raap D.K., Van de Kar L.D. Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sciences. 65(12):1999;1217-1235.
39. Sanchez C., Meier E. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology (Berlin). 129(3):1997;197-205.
40. Saphier D., Zhang K. Inhibition by the serotonin1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin, of antidromically identified paraventricular nucleus neurons in the rat. Brain Research. 615(1):1993;7-12.
41. Seedat S., Stein D.J., Emsley R.A. Open trial of citalopram in adults with post-traumatic stress disorder. International Journal of Neuropsychopharmacology. 3(2):2000;135-140.
42. Seeman T.E., McEwen B.S., Rowe J.W., Singer B.H. Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proceedings of the National Academy of Sciences USA. 98(8):2001;4770-4775.
43. Seifritz E., Baumann P., Muller M.J., Annen O., Amey M., Hemmeter U., Hatzinger M., Chardon F., Holsboer-Trachsler E. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology. 14(4):1996;253-263.
44. Skultetyova I., Kiss A., Jezova D. Neurotoxic lesions induced by monosodium glutamate result in increased adenopituitary proopiomelanocortin gene expression and decreased corticosterone clearance in rats. Neuroendocrinology. 67(6):1998;412-420.
45. Smagin G.N., Howell L.A., Redmann S. Jr., Ryan D.H., Harris R.B. Prevention of stress-induced weight loss by third ventricle CRF receptor antagonist. American Journal of Physiology. 276(5 Pt 2):1999;R1461-R1468.
46. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Safety. 20(3):1999;277-287.
47. Torres G., Horowitz J.M., Laflamme N., Rivest S. Fluoxetine induces the transcription of genes encoding c-fos, corticotropin-releasing factor and its type 1 receptor in rat brain. Neuroscience. 87(2):1998;463-477.
48. Vale W., Spiess J., Rivier C., Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 213(4514):1981;1394-1397.
49. Vigas M., Kvetnansky R., Jurcovicova J., Jezova D., Tatar P. Comparison of catecholamine and adenopituitary hormone responses to various stress stimuli in man. Usdin E., Kvetnansky R., Axelrod J. Stress: The Role of Catecholamines and Other Neurotransmitters. 1984;865-882 Gordon and Breach Science Publishers, New York.
50. Walsh M.T., Dinan T.G. Selective serotonin reuptake inhibitors and violence: a review of the available evidence. Acta Psychiatrica Scandinavica. 104(2):2001;84-91.
51. Welch J.E., Farrar G.E., Dunn A.J., Saphier D. Central 5-HT1A receptors inhibit adrenocortical secretion. Neuroendocrinology. 57(2):1993;272-281.
52. Yirmiya R., Pollak Y., Barak O., Avitsur R., Ovadia H., Bette M., Weihe E., Weidenfeld J. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology. 24(5):2001;531-544.
53. Zohar J., Westenberg H.G. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica Suppl 403. 2000;39-49.
54. Zhang Y., Raap D.K., Garcia F., Serres F., Ma Q., Battaglia G., Van de Kar L.D. Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats. Brain Research. 855(1):2000;58-66.